linagliptin / Generic mfg. - LARVOL DELTA

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=250 | Recruiting | Sponsor: Hoffmann-La Roche | N=410 ➔ 250

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Active, not recruiting | Sponsor: Hoffmann-La Roche | N=675 ➔ 314

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=410 | Recruiting | Sponsor: Hoffmann-La Roche | N=292 ➔ 410

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=307 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=435 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Feb 2024 ➔ Nov 2023

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=380 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Apr 2022 ➔ Nov 2023

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=675 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial primary completion date: Jun 2026 ➔ Sep 2025 | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2027 ➔ Nov 2026

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=470 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Aug 2025 ➔ Nov 2026 | Trial primary completion date: Apr 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=675 | Recruiting | Sponsor: Hoffmann-La Roche | N=470 ➔ 675 | Trial completion date: Nov 2026 ➔ Sep 2027 | Trial primary completion date: Aug 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2026 ➔ Nov 2025

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=435 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2023 ➔ Feb 2024 | Trial primary completion date: Feb 2022 ➔ Jun 2022

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=435 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2023 ➔ Aug 2025 | Trial primary completion date: Feb 2022 ➔ Apr 2024

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=307 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1/2 trial • Non Small Cell Lung Cancer • PD-L1

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis. (PubMed, Andrology) - "This FDA Adverse Event Reporting System-based pharmacovigilance analysis identified potential safety signals linking erectile dysfunction to semaglutide, sitagliptin, and dapagliflozin. These findings do not establish causality and should be regarded as preliminary and hypothesis-generating. Further mechanistic and prospective clinical studies are needed to determine whether these signals reflect true drug-related risks. Clinicians should be aware that erectile dysfunction has been reported in some users of these agents and may consider incorporating sexual health into routine discussions and shared decision-making with male patients."

Journal • Diabetes • Erectile Dysfunction • Metabolic Disorders • Sexual Disorders

SGLT- 2I: "CAN BE A HOPE FOR PERITONEAL DIALYSIS PATIENTS." (ISN-WCN 2026) - "At baseline, his blood pressure was 168/88 mmHg with telmisartan 80 mg/day, amlodipine 10 mg /day, prazosin 10 mg/day, and torsemide 100 mg/day. Other medications were dapagliflozin 10mg/day, linagliptin 5 mg/day, sodium bicarbonate 1000 mg twice daily, insulin, atorvastatin 10mg/day, and aspirin 75 mg/day...There was no hospitalization in this follow-up period.Conclusion As the drug is well tolerated and no adverse effects are noted in this 35-month follow-up, we may hope to use this drug in some dialysis-dependent patients. The findings in this case report need to be confirmed in a large prospective study with a longer follow-up period."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

TWO CASES OF THSD7A-ASSOCIATED MEMBRANOUS NEPHROPATHY WITH BULLOUS PEMPHIGOID (ISN-WCN 2026) - "CaseⅡ-A 73-year-old man with 10-year DM treated with linagliptin developed blisters and edema...In both of our cases, THSD7A was detected along GBM. Further reports and studies are required to elucidate the pathogenic association between THSD7A-associated MN and BP."

Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Renal Disease

GLUCAGON LIKE PEPTIDE-1 MODULATES URINARY SODIUM EXCRETION IN DIABETIC KIDNEY DISEASE VIA ENAC ACTIVATION (ISN-WCN 2026) - "In the present study, we investigated whether linagliptin (LINA), a DPP4 inhibitor (DPP4is), coordinates with SGLT2 inhibitor to attenuate DKD and explored the synergetic effect of LINA in diabetic and hypertensive rodents as well as patients with DM.Methods (1) SDT-fatty rats on high-salt diet were assigned to sham, DKD, DKD+EMPA (12 weeks), or DKD+EMPA 6 weeks then LINA 6 weeks (EMPA+LINA)...High sodium and glucose medium increased ENaC expression and suppressed Nedd4-2 expression, both of which were reversed by co-incubation with GLP-1 or LINA. Among the patients with DM, USE was increased by combination of the two even when compared to EMPA or LINA alone.Conclusion GLP-1 modulates USE in DKD via ENaC activation and improves salt sensitivity, which leads to attenuation DKD."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Fibrosis • Heart Failure • Hypertension • Immunology • Metabolic Disorders • Nephrology • Renal Disease • NEDD4

Comparative Incidence of Bullous Pemphigoid in Patients Treated with DPP-4 Inhibitors Versus Metformin: A Retrospective Cohort Study (AAD 2026) - "Patients with BP diagnoses following treatment with metformin or a DPP-4 inhibitor (alogliptin, saxagliptin, sitagliptin, linagliptin) were identified using ICD-10 and CPT codes. In this large cohort, DPP-4 inhibitors were associated with greater BP risk compared with metformin, with linagliptin showing the strongest effect. Clinicians should maintain awareness of this potential adverse outcome and consider closer dermatologic monitoring or alternative therapies in high-risk patients. Further investigation is warranted to clarify mechanisms and inform safer prescribing practices."

Retrospective data • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

"Synergistic Potential of Linagliptin and Resveratrol in Mitigating Type-II Diabetes-Induced Nephropathy": A Comprehensive Review. (PubMed, Curr Diabetes Rev) - "Resveratrol similarly demonstrates substantial renoprotective benefits through activation of the AMPK/Nrf2 pathway, mitigating oxidative stress and downregulating inflammatory markers such as tumor necrosis factor-alpha and interleukin-1 beta. The synergistic use of linagliptin and resveratrol may provide greater benefits than their individual effects, including improved glycaemic control, reduced renal oxidative stress, and decreased inflammatory and fibrotic markers, thereby offering superior protection against diabetic nephropathy."

Journal • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Type 2 Diabetes Mellitus • IL1B • TNFA

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-, age-, and weight-related differences were noted for dulaglutide, liraglutide, semaglutide, sitagliptin, linagliptin, alogliptin, and saxagliptin. Median onset was shorter for GLP-1 RAs and tirzepatide (≤ 30 days) and longer for DPP-4is (55-132 days), with vildagliptin latest...Musculoskeletal AEs associated with incretin therapies differ by drug class and onset timing. Vigilant monitoring is needed during early GLP-1 RA or tirzepatide therapy and later during DPP-4i use to optimize patient safety."

Adverse events • Journal • Back Pain • Diabetes • Immunology • Metabolic Disorders • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

Evaluation of LG's anticancer acti̇vi̇ty on human gastric cancer cell line HGC-27 via molecular docking and gene expression analysis. (PubMed, Biochem Biophys Res Commun) - "In this study, the anticancer effects of linagliptin (LG), a dipeptidyl peptidase-4 (DPP-4) inhibitor, were evaluated in the human gastric cancer cell line HGC-27...Molecular docking analyses demonstrated favorable binding affinities between LG and key Hedgehog pathway proteins, supporting a potential mechanistic basis for the observed biological effects. Collectively, these findings suggest that LG exhibits antiproliferative and pro-apoptotic activity in gastric cancer cells and may represent a promising candidate for drug repurposing in gastric cancer therapy."

Journal • Preclinical • Gastric Cancer • Oncology • Solid Tumor

Comprehensive experimental and computational evaluation of novel linagliptin-analogues: Synthesis, DFT calculations, molecular modeling, and in vitro anticancer/antioxidant activities. (PubMed, Comput Biol Chem) - "Compound 3h exhibited the highest potency, with IC50 values of 0.66 µM (A549) and 0.29 µM (DLD1), while compounds 3d and 3e showed cytotoxicity comparable to cisplatin. Selectivity index analysis revealed moderate but discernible cancer cell preference, with compound 3h demonstrating the most favorable selectivity toward DLD1 cells (SI = 3.62). These results suggest that compound 3h represents a prioritized candidate within this series and support linagliptin-based azo-imine derivatives as a tractable framework for further structure-activity relationship optimization."

Journal • Preclinical • Oncology

N-LIA-25-297: Bioequivalence clinical trial of two formulations of linagliptin (clinicaltrialsregister.eu) - P1 | N=48 | Completed | Sponsor: Laboratorios Normon S.A.

New P1 trial

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (clinicaltrials.gov) - P4 | N=504 | Active, not recruiting | Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia | Not yet recruiting ➔ Active, not recruiting

Biomarker • Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus